Nexus Opens New Wisconsin Manufacturing Facility
Nexus Pharmaceuticals celebrated a new manufacturing facility in Pleasant Prairie, Wis.
On July 16, 2021, Nexus Pharmaceuticals celebrated the opening of the company’s new manufacturing facility in Pleasant Prairie, Wis.
Facility construction began in August 2019 and was completed in 2021. The Phase I investment of $100 million supports a new, three-story manufacturing facility with an advanced isolator system and multiple lyophilization machines. Commercial production is expected to commence in 2022. The full, multi-phase project is expected to be completed in ten years, which is approximately a $250-million investment.
In February 2021, Nexus announced its support to increase vaccine manufacturing because of the COVID-19 pandemic. With the new manufacturing capacity at the Wisconsin facility, Nexus can maintain the production of existing products and begin manufacturing vaccines without having to sacrifice the production of one drug for another.
The company hopes to bring more than 77 new high-tech manufacturing and science jobs by 2022, creating 400+ new local jobs long-term. According to a company press release, Nexus also intends to partner with local institutions to provide job training and career and research opportunities.
Source: Nexus Pharmaceuticals
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
